ArticleDigestive diseases and sciences2026
VPS33A Promotes Pemigatinib Resistance in Cholangiocarcinoma via Autophagy.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPemigatinib, the inaugural FDA-approved targeted therapy for cholangiocarcinoma (CCA), represents a major advancement in the treatment of this malignancy. Nevertheless, the inevitable emergence of acquired resistance highlights an urgent need for innovative strategies to address this clinical challenge. This study investigates the role of VPS33A in modulating autophagy to mediate Pemigatinib resistance in CCA.
methodsPemigatinib-resistant cell lines were generated through chronic drug exposure. Cell viability and proliferation were evaluated using CCK-8 and EdU experiments. Autophagic flux was assessed using GFP-RFP-LC3 dual fluorescence imaging and transmission electron microscopy, while the interaction between VPS33A and ULK1 was confirmed through correlation analysis. Functional validation was conducted using both in vitro and in vivo experiments.
resultsWe successfully established Pemigatinib-resistant RBE-R and HuCCT1-R cell lines, which exhibited elevated VPS33A expression and autophagy-dependent drug resistance. Mechanistically, VPS33A knockdown reduced ULK1 protein levels, suppressed autophagy, and increased cellular sensitivity to Pemigatinib. In contrast, ULK1 overexpression restored autophagic activity and reversed the enhanced drug sensitivity induced by VPS33A depletion.
conclusionsVPS33A-mediated autophagy sustains Pemigatinib resistance in CCA through ULK1, revealing a targetable vulnerability that could help overcome current therapeutic limitations.
Indexed as
Identifiers
41718964What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.